Zentalis Pharmaceuticals Inc. logo

Zentalis Pharmaceuticals Inc.

ZNTL | NASDAQ
Chart Builder DCF Calculator
$3.08
+$0.05 (+1.65%)
Sep 22, 2026, 11:40 AM ET · Market open

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Key Executives

Name Position
Julie Eastland Chief Executive Officer, President & Director
James Bucher Chief Legal Officer & Corporate Secretary
Wendy Chang Chief People Officer
Haibo Wang Chief Business Officer
Henry Gu Senior Vice President & Head of Intellectual Property
Ingmar Bruns Chief Medical Officer
Rajesh Israni Executive VP of Regulatory Affairs & Medical Writing
Robert J. DiVasto Chief Technical Officer
Sarah Kelly Senior Vice President of Commercial Strategy
Vincent Vultaggio SVP of Finance & Principal Accounting Officer

Latest SEC Filings

Date Type Title
Aug 19, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 19, 2026 4 Filing
Aug 14, 2026 8-K Current Report
Aug 14, 2026 424B5 Filing
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 424B5 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jun 18, 2026 4 Filing
View All SEC Filings
Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc. logo
Country United States
IPO Date Apr 2, 2020
Industry Biotechnology
Sector Healthcare
Employees 106
CEO Julia Marie Eastland

Contact Details

10275 Science Center Drive San Diego, California 92121 United States

Stock Details

Ticker Symbol ZNTL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001725160
CUSIP Number 98943L107
ISIN Number US98943L1070
SIC Code 2834

© 2026 bestshares.com. All rights reserved.